With advances in understanding the structure of NMDA receptor, NR2B antagonist is expected to be a more effective candidate with little side effect to treat these diseases.

• 而NMDA受体NR2B亚单位分布相对集中,选择性NR2B拮抗剂有望成为更安全、有效、副作用低的一类新型药物。